{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-002118","form_type":"8-K","ticker":"STAA","cik":"0000718937","company_name":"STAAR SURGICAL CO","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.865236+00:00","generated_at":"2026-06-19T07:28:17.178966+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"STAAR Surgical Q4 net sales $64M, ICL units +20% YoY; FY2023 ICL sales guidance ~$340M","bullets":["Q4 net sales $64.0M (+9% YoY); constant currency net sales $67.9M (+15%).","ICL sales $61.2M (+15% YoY); ICL units +20% YoY; U.S. ICL units +109%.","FY2022 net sales $284.4M (+23%); ICL sales $269.7M (+27%); ICL units +33%.","FY2022 GAAP EPS $0.78 vs $0.50 prior year; adjusted EPS $1.22 vs $0.87.","FY2023 ICL sales guidance ~$340M, representing 26% YoY growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-002118","json":"https://secwatch.observer/filing/0001564590-23-002118.json","markdown":"https://secwatch.observer/filing/0001564590-23-002118.md","text":"https://secwatch.observer/filing/0001564590-23-002118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/718937/000156459023002118/0001564590-23-002118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/718937/000156459023002118/staa-8k_20230221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:28:17.178966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77faf5d25fc3d82586f86474017c80826eda0528","claim":"STAAR SURGICAL CO reported fourth quarter and fiscal year ended December 30, 2022 results: revenue $64.0 million, net income $0.12 per diluted share, EPS $0.12 per diluted share. Guidance reaffirmed.","evidence_excerpt":"of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview • Net Sales of $64.0 Million Up 9% and Constant Currency Net Sales of $67.9 Million Up 15% from Prior Year Quarter • ICL Sales of $61.2 Million Up 15% and Constant Currency ICL Sales of $64.3 Million Up 21%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459023002118/0001564590-23-002118-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 30, 2022"},{"label":"Revenue","value":"$64.0 million"},{"label":"Net income","value":"$0.12 per diluted share"},{"label":"EPS","value":"$0.12 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}